Literature DB >> 10834998

Comparison of a new colorimetric assay with the NCCLS broth microdilution method (M-27A) for antifungal drug MIC determination.

R K Li1, C M Elie, G E Clayton, M A Ciblak.   

Abstract

We evaluated a new microtiter assay for antifungal susceptibility testing based on a colorimetric reaction to monitor fungal substrate utilization. This new method (rapid susceptibility assay [RSA]) provides quantitative endpoint readings in less than 8 h compared with visual determination of MIC by the National Committee for Clinical Laboratory Standards (NCCLS) broth microdilution method, which requires a minimum of 48 h of incubation. In this study, we tested clinical isolates from each of the following species: Candida albicans (20 isolates), C. glabrata (20 isolates), C. krusei (19 isolates), C. tropicalis (19 isolates), and C. parapsilosis (28 isolates). RSA and NCCLS broth dilution methods were used to determine the MICs of amphotericin B, fluconazole, itraconazole, and 5-flucytosine for all 106 isolates. RPMI 1640 medium buffered with morpholinopropanesulfonic acid was used for both methods; however, glucose and inoculum concentrations in the RSA were modified. RSA MICs were determined as the lowest drug concentration that prevented glucose consumption by the organism after 6 h of incubation. MICs obtained from the RSA were compared with those obtained from the NCCLS M-27A method read at 24 and 48 h. MIC pairs were considered in agreement when the difference between the pairs was within 2 twofold dilutions. For the 106 isolates tested, amphotericin B and 5-flucytosine demonstrated the highest agreement in MICs between the two methods (100 and 98%, respectively), whereas fluconazole and itraconazole produced less favorable MIC agreement (63.2 and 61.3%, respectively). The azole MIC differences between the two methods were significantly reduced when lower inocula were used with a prolonged incubation time. This preliminary comparison suggests that this rapid procedure may be a reliable tool for the in vitro determination of MICs of amphotericin B and 5-flucytosine and warrants further evaluation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10834998      PMCID: PMC86796          DOI: 10.1128/JCM.38.6.2334-2338.2000

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  Determination of antifungal MICs by a rapid susceptibility assay.

Authors:  M H Riesselman; K C Hazen; J E Cutler
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic.

Authors:  M A Pfaller; R N Jones; S A Messer; M B Edmond; R P Wenzel
Journal:  Diagn Microbiol Infect Dis       Date:  1998-02       Impact factor: 2.803

Review 3.  The new fungal opportunists are coming.

Authors:  J R Perfect; W A Schell
Journal:  Clin Infect Dis       Date:  1996-05       Impact factor: 9.079

Review 4.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors:  J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

5.  Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods.

Authors:  J N Galgiani; J Reiser; C Brass; A Espinel-Ingroff; M A Gordon; T M Kerkering
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 6.  Systemic fungal infections: major problems in cancer patients.

Authors:  R L Powles; J Mehta
Journal:  Indian J Cancer       Date:  1994-09       Impact factor: 1.224

Review 7.  Antifungal susceptibility testing of yeasts: a brief overview.

Authors:  D J Sheehan; A Espinel-Ingroff; L S Moore; C D Webb
Journal:  Clin Infect Dis       Date:  1993-11       Impact factor: 9.079

8.  Fluconazole versus Candida albicans: a complex relationship.

Authors:  J R Graybill; E Montalbo; W R Kirkpatrick; M F Luther; S G Revankar; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.

Authors:  R A Fromtling; J N Galgiani; M A Pfaller; A Espinel-Ingroff; K F Bartizal; M S Bartlett; B A Body; C Frey; G Hall; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

  9 in total
  2 in total

1.  Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods.

Authors:  Maria José Linares; Guadalupe Charriel; Francisco Solís; Fernando Rodriguez; Ana Ibarra; M Casal
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

2.  Modified colorimetric assay for susceptibility testing of azole antifungal drugs against Candida species.

Authors:  Jian Chen; Zhe Wan; Ruoyu Li
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.